• Rein Therapeutics Inc RNTX.OQ reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -86 cents. The mean expectation of two analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -28 cents to -21 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Rein Therapeutics Inc's reported EPS for the quarter was a loss of 25 cents​.

• The company reported a quarterly loss of $5.5 million.

• Rein Therapeutics Inc shares had risen by 33.3% this quarter and gained 2.6% so far this year.

FORECAST CHANGES

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Rein Therapeutics Inc is $10.00

This summary was machine generated from LSEG data May 16 at 08:02 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)